Volition Signs Co-Marketing and Services Agreement with Hologic
VolitionRx (NYSE AMERICAN: VNRX) has signed a co-marketing agreement with Hologic Diagenode for its Nu.Q® Discover service, which provides epigenetic profiling solutions for drug development and research. The initial one-year agreement could potentially lead to Hologic becoming an exclusive provider of these services.
The Nu.Q® Discover program has an estimated total addressable market of $200 million annually. The partnership leverages Hologic's extensive experience and large client base, having recorded revenues exceeding $4 billion in 2024. The collaboration aims to expand Volition's presence in the pharmaco-epigenetics market by incorporating nucleosome-based biomarkers into Hologic's portfolio for various disease areas including oncology, cardiovascular, and neurodegenerative conditions.
- Partnership with Hologic, a company with $4 billion in 2024 revenue, expanding market reach
- Access to Nu.Q® Discover's $200 million total addressable market
- Potential for exclusive provider agreement with Hologic if successful
- Strong validation of Volition's nucleosome-based biomarkers in clinical development
- Initial agreement limited to one year
- Exclusive provider status dependent on meeting undisclosed terms
Insights
Volition's partnership with Hologic expands market reach for their epigenetic testing service, potentially accelerating revenue in the $200M pharmaco-epigenetics market.
Volition's new co-marketing agreement with Hologic represents a strategic expansion of its Nu.Q® Discover service distribution channels. This partnership gives Volition access to Hologic's extensive client network, which spans biotech, pharmaceutical, academic, and government organizations. For context, Hologic is a significant player with
The agreement follows a measured approach - starting with a one-year co-marketing term that could evolve into an exclusive provider arrangement if successful. This structure minimizes risk while testing market fit before deeper integration.
The Nu.Q® Discover platform offers significant value in the growing pharmaco-epigenetics field. By quantifying nucleosomes, the technology helps identify epigenetic signatures tied to disease states and treatment responses across multiple therapeutic areas including oncology, cardiovascular, neurodegenerative, and immunology.
This deal addresses a critical commercialization challenge for specialized diagnostic companies - accessing a broad customer base without building an extensive sales force. By leveraging Hologic's established distribution network and conference presence, Volition can accelerate market penetration in what they estimate as a
The partnership provides third-party validation of Nu.Q® technology's clinical utility while potentially accelerating Volition's revenue growth trajectory in this specialized market segment.
The Nu.Q® Discover service provides drug developers and scientists with a range of state-of-the-art assays for rapid epigenetic profiling in disease model development, preclinical testing, and clinical studies from discovery to being market ready.
Under the agreement, Hologic (NASDAQ: HOLX) will co-market Nu.Q® Discover services of Volition with Hologic Customers for an initial one-year term. If successful, the aim is for Hologic to be appointed as an exclusive provider of those services, subject to further terms being agreed.
Dr. Jasmine Kway, Chief Executive Officer, Singapore Volition, said:
"This is a significant milestone for our Nu.Q® Discover program and will greatly expand customer access to our proprietary Nu.Q® Discover assays, which have an estimated total addressable market of
"Hologic has extensive experience, recording revenues of over
"The inclusion of our nucleosome-based biomarkers in Hologic's portfolio demonstrates a strong validation of their value in clinical development.
"We look forward to working with the Hologic team as we strengthen our position in the pharmaco-epigenetics market, to help us to grow our revenues."
Raphael Werding, Head of Life Sciences, Hologic, said:
"We are delighted to sign this agreement and add Nu.Q® Discover to our service offering. At Hologic, we have extensive experience not only in oncology but also in other disease areas such as cardiovascular, neurodegenerative, immunology and others; disease areas where we believe nucleosome quantification can provide additional valuable biological insights to our biotech, pharma and academic clients."
"By incorporating Nu.Q® Discover biomarkers into a client's study design we may identify specific epigenetic signatures associated with disease states and treatment responses and in turn help advance the field of personalized medicine."
"Our ultimate goal is to create value for our clients by helping match patients with the therapies most likely to benefit them, while sparing them from treatments unlikely to be effective."
"We are excited to immediately start marketing Nu.Q® Discover at conferences and webinars and look forward to a long term and fruitful collaboration with Volition."
About Nu.Q® Discover
Volition's Nu.Q® Discover program enables drug developers and scientists access to a range of state-of-the-art assays for rapid epigenetic profiling in disease model development, preclinical testing, and clinical studies from discovery to being market ready.
Nu.Q® Discover is built on proprietary nucleosome quantification technology. It is a valuable research tool for R&D professionals working within the field of pharmaco-epigenetics, studying the epigenetic basis for variation in response to drugs.
About Hologic, Inc.
Hologic, Inc. (NASDAQ: HOLX), is dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world.
One of its subsidiaries is Hologic Diagenode, a leading provider in the field of epigenomics, with over 20 years of expertise. Their services can help advance biomarker discovery and validation by combining the strengths of epigenomics and bioinformatics. This new dimension of epigenomics can offer novel insights that extend beyond genomics, aiding in early detection, patient screening, minimal residual disease (MRD) monitoring, and much more. They partner with clients to create a customized, end-to-end service utilizing the best available technology to shorten timelines for translational research and biomarker validation before clinical trials.
To learn more, visit www.hologic.com.
About Volition
Volition is a multi-national epigenetics company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620
Investor Relations
Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com, +1-212-915-2568
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, , the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this press release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
1.Data on file, Volition Total Addressable Market Model
View original content:https://www.prnewswire.com/news-releases/volition-signs-co-marketing-and-services-agreement-with-hologic-302569548.html
SOURCE VolitionRx Limited
FAQ
What is the new partnership between VolitionRx (VNRX) and Hologic?
What is the market potential for VNRX's Nu.Q® Discover program?
How will the Hologic partnership benefit VolitionRx (VNRX)?
What disease areas will VNRX's Nu.Q® Discover target through the Hologic partnership?
When will Hologic begin marketing VNRX's Nu.Q® Discover service?
